ReviewImmunological reviews2024
Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.
Review in Immunological reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- A First-in-Human, Single- and Multiple-Dose Study of APG777, a Half-Life-Extended Anti-IL-13 Monoclonal Antibody, in Healthy Volunteers.Clinical and translational science · 2025Trial
- Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review.Human vaccines & immunotherapeutics · 2026Review
- Integrated Traditional Chinese and Western Medicine for Chronic Spontaneous Urticaria: Protocol for a Trials Within Cohorts Study.JMIR research protocols · 2026Article
- Therapeutic Applications of Immunobiologics in Autoimmune and Inflammatory Diseases.Pharmaceutics · 2026Review
- Anti-Allergic Potential of Chamaecrista nomame and Its Compound Luteolin for Novel Asthma Therapy.Phytotherapy research : PTR · 2026Article
- Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.Nature reviews. Drug discovery · 2026Review
- The Therapeutic Potential of Farm Dust Extracts in a Mouse Model of Eosinophilic Inflammation.Allergy · 2026Article
- Article
- RNA-binding protein tristetraprolin inhibits Th2 cell activation and differentiation in allergic rhinitis by promoting TRIM18 mRNA decay.The Journal of biological chemistry · 2026Article
- [Allergens induce activation of blood CCR3Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- A prospective cohort study of ultra-rush subcutaneous immunotherapy in dust mite-induced allergic rhinitis.The World Allergy Organization journal · 2026Article
- Genetic predisposition to elevated total immunoglobulin E levels defines a distinct adult-onset-predominant asthma phenotype.Scientific reports · 2026Article
- Gold Nanoparticle-Based Systems for Targeting the Ara h2 Allergen: A Molecular Modeling Approach.Computational and structural biotechnology journal · 2026Article
- Distributional characteristics analysis of aeroallergens among children With allergic respiratory diseases in Sichuan province, China.Frontiers in pediatrics · 2026Article
- Immunological and molecular biomarkers in skin allergy therapy: monitoring inflammation, barrier function, and treatment response.Postepy dermatologii i alergologii · 2026Review
- IgE, anti-IgE therapy, and regulatory T cells: new paradigms in allergic inflammation.Frontiers in allergy · 2026Review
- Targeting type 2 inflammation in dermatology: mechanisms and clinical implications.Frontiers in immunology · 2026Review
- Article
- Using Biologics in the Prevention of Anaphylaxis.Current allergy and asthma reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The etiology of allergy is closely linked to type 2 inflammatory responses ultimately leading to the production of allergen-specific immunoglobulin E (IgE), a key driver of many allergic conditions. At a high level, initial allergen exposure disrupts epithelial integrity, triggering local inflammation via alarmins including IL-25, IL-33, and TSLP, which activate type 2 innate lymphoid cells as well as other immune cells to secrete type 2 cytokines IL-4, IL-5 and IL-13, promoting Th2 cell development and eosinophil recruitment. Th2 cell dependent B cell activation promotes the production of allergen-specific IgE, which stably binds to basophils and mast cells. Rapid degranulation of these cells upon allergen re-exposure leads to allergic symptoms. Recent advances in our understanding of the molecular and cellular mechanisms underlying allergic pathophysiology have significantly shaped the development of therapeutic intervention strategies. In this review, we highlight key therapeutic targets within the allergic cascade with a particular focus on past, current and future treatment approaches using monoclonal antibodies. Specific targeting of alarmins, type 2 cytokines and IgE has shown varying degrees of clinical benefit in different allergic indications including asthma, chronic spontaneous urticaria, atopic dermatitis, chronic rhinosinusitis with nasal polyps, food allergies and eosinophilic esophagitis. While multiple therapeutic antibodies have been approved for clinical use, scientists are still working on ways to improve on current treatment approaches. Here, we provide context to understand therapeutic targeting strategies and their limitations, discussing both knowledge gaps and promising future directions to enhancing clinical efficacy in allergic disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.